Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Parker Acquires SciLog to Strengthen Single-use System Capability

Published: Friday, August 24, 2012
Last Updated: Thursday, August 23, 2012
Bookmark and Share
Acquisition will allow Parker to deliver an enhanced bioprocessing portfolio.

Parker Hannifin Corporation has announced the acquisition of SciLog Inc, a provider of unique and proprietary single-use technologies and systems for the biopharmaceutical market to support their on-going development as a key supplier to the growing single-use market.

The acquisition will allow Parker to deliver an enhanced bioprocessing portfolio combining filtration and separation expertise, disposable bag systems and automated single-use solutions.

SciLog will be integrated into Parker's Process Filtration Division, which provides high-purity filtration and separation solutions coupled with disposable bags and tubing assemblies for applications such as cell culture media and buffer preparation, product stream filtration and sterile fill finish.

Parker's offering to customers will be enhanced through the addition of SciLog's patented sensor technology for process monitoring and control coupled with unique automation technology from lab to production scale in upstream and downstream processing.

"The addition of SciLog perfectly complements our existing core strengths in filtration and disposable assemblies for the biopharmaceutical market," said Dr Mike Brailsford, General Manager at Parker's Process Filtration Division.

Dr Brailsford continued, "Our customers will now benefit from complete, turnkey solutions that enhance productivity, increase cost-effectiveness and facilitate processing units of operation such as buffer / media prep, virus inactivation etc."

"Today SciLog becomes a global business," said Juliette Schick, CEO and President of SciLog, "With this acquisition SciLog now has a platform in Parker to access global markets, distribution channels and resources to maximize SciLog's single-use product offerings and patent positions."

Parker's expanded capabilities in the biopharmaceutical market will be delivered globally through an extensive and growing global technical support network coupled with customer support centres in over 50 countries.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!